ASLAN 003

Drug Profile

ASLAN 003

Alternative Names: ASLAN003; LAS 186323

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.; ASLAN Pharmaceuticals
  • Class Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Preclinical Cancer
  • No development reported Rheumatoid arthritis
  • Discontinued Multiple sclerosis

Most Recent Events

  • 20 Aug 2018 ASLAN 003 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 05 Jan 2018 Phase-II clinical trials in Acute myeloid leukaemia in Australia, Singapore (PO) (NCT03451084)
  • 13 Nov 2017 Singapore’s Health Sciences Authority approves IND application for initiation of a phase II trial in Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top